ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Setting research priorities at NIH

June 7, 2004 | APPEARED IN VOLUME 82, ISSUE 23

NIH Director Elias A. Zerhouni and three NIH institute heads testified before the House Energy & Commerce Committee’s Health Subcommittee hearing last week on how the agency decides what areas of research to fund. The hearing, which is one of a series on the structure and goals of NIH, was not intended to focus on the agency’s peer-review process, but on the origins of its 27 institutes and centers, according to the committee chairman, Joe Barton (R-Texas). During questioning, Barton asked Zerhouni whether he would create the current structure if he had the opportunity to set up the research agency from scratch. Zerhouni replied that he would not, and would instead create an evolving structure that changes with arising needs. This led Barton to raise the issue of including restructuring legislation as part of an NIH reauthorization package he plans to introduce in this congressional term. He asked all four witnesses whether it would be more effective for Congress to legislate a new structure or to give the director’s office the authority to restructure the agency as needed. The panel agreed that, to ensure the necessary flexibility to respond to emerging issues, the authority to make changes should reside with the NIH director.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment